Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Cwm LLC Cuts Stock Holdings in Mersana Therapeutics, Inc. $MRSN
03:43am, Thursday, 22'nd Jan 2026
Cwm LLC lowered its position in shares of Mersana Therapeutics, Inc. (NASDAQ: MRSN) by 96.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights
06:55pm, Tuesday, 23'rd Dec 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
BALA CYNWYD, Pa. , Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
MILWAUKEE , Dec. 16, 2025 /PRNewswire/ -- The Ademi Firm continues to investigate Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced t
NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights
03:24pm, Monday, 08'th Dec 2025
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights
12:41pm, Friday, 28'th Nov 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN
06:14pm, Thursday, 27'th Nov 2025
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), who has recovere
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
03:19pm, Friday, 14'th Nov 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
09:10am, Friday, 14'th Nov 2025
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.44. This compares to a loss of $2.25 per share a year ago.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. (NASDAQ: MRSN)
05:30pm, Thursday, 13'th Nov 2025
NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders an
Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript
04:51pm, Thursday, 13'th Nov 2025
Mersana Therapeutics, Inc. ( MRSN ) M&A Call November 13, 2025 8:00 AM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Di
Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
11:35am, Thursday, 13'th Nov 2025
MILWAUKEE , Nov. 13, 2025 /PRNewswire/ -- The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced transacti
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
10:15am, Thursday, 13'th Nov 2025
Day One Biopharmaceuticals (NASDAQ: DAWN) on Thursday agreed to acquire Mersana Therapeutics Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug
